Statins Neuromuscular Adverse Effects

被引:67
作者
Attardo, Silvia [1 ]
Musumeci, Olimpia [1 ]
Velardo, Daniele [2 ]
Toscano, Antonio [1 ]
机构
[1] Univ Messina, Dept Clin & Expt Med, Unit Neurol & Neuromuscular Disorders, I-98125 Messina, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neurosci, Neuromuscular & Rare Dis Unit, I-20122 Milan, Italy
关键词
statins and myopathy; muscle adverse effects; neuromuscular complications; peripheral neuropathy; myasthenia; CREATINE-KINASE; MUSCLE; MYOPATHY; SYMPTOMS; RHABDOMYOLYSIS; COENZYME-Q10; SYSTEM; IMPACT; RARE;
D O I
10.3390/ijms23158364
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscular side effects that represent about two-third of all adverse events. Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis. Moreover, they may lead to peripheral neuropathy and induce or unmask a preexisting neuromuscular junction dysfunction. A clinical follow up of patients assuming statins could reveal early side effects that may cause neuromuscular damage and suggest how to better modulate their use. In fact, statin dechallenge or cessation, or the alternative use of other lipid-lowering agents, can avoid adverse events. This review summarizes the current knowledge on statin-associated neuromuscular adverse effects, diagnosis, and management. It is conceivable that the incidence of neuromuscular complications will increase because, nowadays, use of statins is even more diffused than in the past. On this purpose, it is expected that pharmacogenomic and environmental studies will help to timely predict neuromuscular complications due to statin exposure, leading to a more personalized therapeutic approach.
引用
收藏
页数:15
相关论文
共 88 条
[1]   Statin-induced myopathy: a review and update [J].
Abd, Thura T. ;
Jacobson, Terry A. .
EXPERT OPINION ON DRUG SAFETY, 2011, 10 (03) :373-387
[2]   Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics [J].
Abed, Waddah ;
Abujbara, Mousa ;
Batieha, Anwar ;
Ajlouni, Kamel .
ANNALS OF MEDICINE AND SURGERY, 2022, 74
[3]   Neuromuscular Complications of Statins [J].
Ahn, Sung C. .
PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA, 2008, 19 (01) :47-+
[4]  
Al-Kuraishy Hayder M, 2019, J Pak Med Assoc, V69(Suppl 3), pS108
[5]   Diagnosis and Management of Statin Intolerance [J].
Alonso, Rodrigo ;
Cuevas, Ada ;
Cafferata, Alberto .
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2019, 26 (03) :207-215
[6]   The role of mitochondria in statin-induced myopathy [J].
Apostolopoulou, Maria ;
Corsini, Alberto ;
Roden, Michael .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2015, 45 (07) :745-754
[7]  
Arca M, 2012, PANMINERVA MED, V54, P105
[8]   Statins and the neuromuscular system: a neurologist's perspective [J].
Argov, Z. .
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (01) :31-36
[9]   A neuromuscular approach to statin-related myotoxicity [J].
Baker, Steven K. ;
Samjoo, Imtiaz A. .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2008, 35 (01) :8-21
[10]   Creatine as a Candidate to Prevent Statin Myopathy [J].
Balestrino, Maurizio ;
Adriano, Enrico .
BIOMOLECULES, 2019, 9 (09)